Compare Revvity Inc (RVTY) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Revvity Inc trades at $115.96 (market cap $12.91B), while Vanguard Ultra Short Bond ETF trades at $49.7. The key difference: Revvity Inc pays a 0.24% dividend while Vanguard Ultra Short Bond ETF pays none, and Revvity Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| RVTY | VUSB | |
|---|---|---|
Market Cap | $12.91B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $117.75 | $50.03 |
52-Week Low | $82.26 | $49.60 |
Enterprise Value | $15.23B | — |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
VUSB trades at $49.695, up 0.07% on the day, with a bearish technical outlook indicated by moving averages and ADX signals. Recent news highlights short-term bond ETF appeal amid potential Fed rate hikes. Financial ratios are unavailable, but the fund maintains consistent dividend distributions, with recent payouts around $0.17-$0.18 per share.
The outlook is cautious due to bearish technicals and interest rate sensitivity. Opportunities lie in short-term bond stability if rates rise, but risks include Fed policy shifts and market volatility. Investors should weigh dividend consistency against broader fixed-income pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
